TABLE 3.
Additional secondary efficacy results: M‐ITT population
| Efficacy endpoints | Lithium IR | Lithium PR | |
|---|---|---|---|
| Q‐LES‐Q‐SF percentage maximum possible total score changes | Mean (± SD);95% CI | ||
| Week 1 | 1.49 (6.50); −0.75/3.72 | −0.73 (7.22); −3.29/1.83 | |
| Week 12 | 1.32 (9.47); −2.15;4.80 | 0.50 (11.13); −4.00/5.00 | |
| CGI | |||
| Week 1 | |||
| Improved | n (%) | 8 (58.1) | 19 (54.3) |
| No change | 24 (68.6) | 14 (40) | |
| worsened | 3 (8.6) | 2 (5.8) | |
| Week 12 | |||
| Improved | 18 (58.1) | 19 (70.3) | |
| No change | 11 (35.5) | 5 (18.5) | |
| worsened | 2 (6.5) | 3 (11.1) |
Abbreviations: GI, clinical global improvement; Q‐LES‐Q‐SF, Quality of Life Enjoyment and Satisfaction Questionnaire‐short Form.